Actively Recruiting

Age: 18Years +
All Genders
NCT06628921

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

Led by University of Florence · Updated on 2026-01-21

50

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

U

University of Florence

Lead Sponsor

S

Società Italiana per lo Studio delle Cefalee

Collaborating Sponsor

AI-Summary

What this Trial Is About

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)

CONDITIONS

Official Title

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III)
  • At least 8 days of migraine per month
  • Adequate compliance with study procedures
  • Availability of a migraine diary for at least one month prior to enrollment
  • Ongoing attack before administration
  • Included in the TACHIS study (NCT06409845)
Not Eligible

You will not qualify if you...

  • Subjects with contraindications to the use of eptinezumab
  • Concomitant diagnosis of medical conditions and/or comorbidities that could interfere with the study's assessments and outcomes
  • Pregnancy and breastfeeding
  • Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Campus Biomedico

Roma, Italy

Actively Recruiting

Loading map...

Research Team

F

Fabrizio Vernieri, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here